Last updated: September 24, 2026
GONITRO is a prescription nitroglycerin sublingual powder approved by the U.S. Food and Drug Administration for acute relief of an angina attack in patients with coronary artery disease. Its commercial differentiation comes from unit-dose powder delivery rather than a novel active ingredient. The core excipient opportunity is therefore in powder flow, content uniformity, rapid dissolution, moisture protection, taste control, and device or sachet performance.
The labeled inactive ingredients are mannitol, povidone, and sodium starch glycolate. The formulation does not require a complex lipid, polymeric film, or controlled-release matrix. This creates relatively low technical barriers for excipient suppliers, but the low dose of nitroglycerin creates significant content-uniformity and stability risks for competitors.
| Attribute |
GONITRO profile |
| Active ingredient |
Nitroglycerin |
| Strength |
0.4 mg per packet |
| Dosage form |
Sublingual powder |
| Route |
Oral transmucosal |
| Indication |
Acute relief or prophylaxis of angina attacks |
| Reference sponsor |
AcelRx Pharmaceuticals, Inc. |
| FDA application |
NDA 208255 |
| Key excipients |
Mannitol, povidone, sodium starch glycolate |
| Administration |
Powder poured under the tongue |
| Primary technical risks |
Low-dose uniformity, moisture, powder adhesion, dissolution, packaging |
| Regulatory category |
Small-molecule drug product |
What is GONITRO and how does its formulation work?
GONITRO delivers nitroglycerin directly to the sublingual mucosa. The formulation is designed to disintegrate and dissolve rapidly in a small volume of saliva, allowing transmucosal absorption and reducing dependence on gastrointestinal absorption and hepatic first-pass metabolism.
Mannitol is the principal diluent and bulking agent. It is suitable for oral powders because it is relatively nonhygroscopic, has an acceptable mouthfeel, and can support rapid dissolution. Povidone functions as a binder and may improve particle adhesion and blend uniformity. Sodium starch glycolate is a superdisintegrant that promotes rapid breakup when the powder contacts saliva.
The formulation strategy is commercially important because nitroglycerin is present at a very low dose relative to the total powder mass. Small segregation differences during blending, filling, transport, or packet opening can produce clinically relevant dose variation. Excipients must therefore support uniform distribution rather than only rapid dissolution.
Which excipients protect GONITRO performance?
Mannitol as the bulk diluent
Mannitol is the most commercially important excipient in the GONITRO platform. Its value derives from four properties:
- It increases the powder mass sufficiently to support accurate filling.
- It has a relatively dry, cooling mouthfeel.
- It is widely accepted in oral solid dosage forms.
- It generally has lower moisture uptake than many alternative polyols.
Potential commercial improvements include:
- Direct-compression or spray-dried mannitol grades with improved flow.
- Narrower particle-size distributions to reduce segregation.
- Co-processed mannitol systems designed for faster wetting.
- Low-endotoxin or specialty grades for tightly controlled pharmaceutical supply chains.
- Mannitol grades optimized for sachet filling and electrostatic control.
A replacement mannitol grade would need to maintain assay uniformity, dissolution, packet fill accuracy, and sensory acceptability. A change in grade could require comparative pharmaceutical development and, depending on the scope, a post-approval supplement under FDA change-control rules.
Povidone as binder and uniformity aid
Povidone can improve cohesion and reduce separation between nitroglycerin-containing particles and the mannitol carrier. Its molecular weight, particle size, residual moisture, and grade selection affect flow and dissolution.
Commercial opportunities include:
- Low-moisture povidone grades.
- Spray-dried povidone for improved blending.
- Lower-viscosity grades that minimize delayed dissolution.
- Co-processed mannitol-povidone excipients.
- Povidone grades with tighter control of peroxide and aldehyde impurities.
Nitroglycerin is an energetic organic nitrate and requires conservative control of heat, friction, contamination, and reactive impurities. Excipient suppliers that can document low impurity burdens and consistent moisture profiles have an advantage over commodity suppliers.
Sodium starch glycolate as a disintegrant
Sodium starch glycolate supports rapid dispersion after contact with saliva. The relevant performance variables are swelling capacity, particle-size distribution, substitution level, moisture content, and source material.
Potential product opportunities include:
- Fast-wetting sodium starch glycolate grades.
- Lower-swelling grades that reduce mouthfeel and residue.
- Co-processed disintegrant systems that improve dispersibility without increasing bulk.
- Excipient blends engineered for sublingual powders rather than conventional tablets.
The commercial challenge is balancing rapid breakup with powder flow. Excessive swelling can increase residue or create an unpleasant oral sensation. Insufficient disintegration can delay release and weaken the product’s sublingual positioning.
What excipient strategies could improve GONITRO?
Moisture-control strategy
Moisture is the central stability concern for a nitroglycerin powder. It can alter powder flow, promote agglomeration, change excipient behavior, and affect dissolution. The most practical improvement is usually packaging rather than a new excipient.
Relevant options include:
- High-barrier foil laminate sachets.
- Low-moisture excipient grades.
- Desiccant-enabled secondary packaging.
- Nitrogen-flushed or low-oxygen packaging where supported by stability data.
- Moisture-indicator controls during manufacturing and distribution.
- Reduced headspace and improved packet seal integrity.
Any moisture-control strategy must also address dose recovery. Powder that adheres to the packet interior can reduce delivered dose even when the nominal fill weight is correct.
Particle engineering
Particle engineering may create a stronger technical position than simple excipient substitution. Options include:
- Spray-dried mannitol-povidone carrier particles.
- Ordered mixtures in which nitroglycerin is deposited onto a larger carrier.
- Granulated blends with controlled porosity.
- Narrow particle-size fractions to reduce segregation.
- Surface-treated carriers that reduce electrostatic adhesion.
- Engineered porous particles for fast saliva penetration.
The primary development target should be delivered-dose uniformity after packet opening, not only blend assay. Testing should evaluate partial transfer, powder retention, agglomeration, and patient handling.
Taste and mouthfeel optimization
Nitroglycerin can produce an unpleasant taste or oral sensation. Mannitol provides a cooling effect that can improve acceptability, but sweetness and cooling intensity must remain compatible with rapid administration. Adding a flavor system may create regulatory and stability complications because flavor components can introduce volatile impurities, moisture, or extractables.
A low-risk strategy is to optimize mannitol grade and particle engineering before adding new flavor excipients. If taste masking is required, the selected material must not delay sublingual dissolution or create a coating effect around nitroglycerin particles.
Excipient alternatives
Potential alternatives include lactose, sorbitol, xylitol, microcrystalline cellulose, crospovidone, and low-substituted hydroxypropyl cellulose. Their commercial usefulness is limited by the product’s requirements.
| Candidate |
Potential benefit |
Principal concern |
| Lactose |
Low cost and broad supply |
Moisture, reducing-sugar chemistry, taste |
| Sorbitol |
Solubility and sweetness |
Hygroscopicity and possible stickiness |
| Xylitol |
Sweetness and cooling |
Cost, hygroscopicity, gastrointestinal tolerance |
| Crospovidone |
Rapid wicking and disintegration |
Particle segregation and mouthfeel |
| Microcrystalline cellulose |
Good flow and compaction |
Poor solubility and possible residue |
| Low-substituted HPC |
Disintegration support |
Lower solubility and sensory impact |
| Spray-dried mannitol |
Flow and filling performance |
Supplier qualification and process dependence |
Mannitol remains the strongest baseline excipient because it combines acceptable sensory properties with relatively manageable moisture behavior.
What commercial opportunities exist for excipient suppliers?
Premium pharmaceutical mannitol
A supplier could pursue a specialized mannitol grade for sublingual powders. The value proposition would include:
- Controlled particle-size distribution.
- Low moisture and low hygroscopicity.
- Improved flow through small sachet openings.
- Reduced electrostatic adhesion.
- Consistent dissolution in low saliva volumes.
- Compatibility with high-shear blending.
This market is likely to be modest in volume but attractive in margin because the product is low-dose, prescription, and quality-sensitive.
Co-processed excipient platforms
A co-processed mannitol-povidone or mannitol-disintegrant system could reduce formulation development time for nitroglycerin and other low-dose oral powders. The platform could also target:
- Sublingual analgesics.
- Buccal opioids and non-opioids.
- Antiemetic powders.
- Pediatric oral powders.
- Emergency cardiovascular products.
- Oral rescue medications.
The strongest commercial position would come from demonstrating uniformity at low drug loading and rapid dispersion without specialized manufacturing equipment.
Packaging and excipient integration
For GONITRO-type products, packaging is part of the dosage-form performance. Suppliers could offer integrated solutions combining:
- Low-moisture excipients.
- High-barrier sachet films.
- Controlled-fill equipment.
- Antistatic packet materials.
- Stability-indicating packaging configurations.
This approach may be more defensible than selling a commodity excipient because it links material performance to delivered dose and shelf life.
Generic and authorized-generic formulation support
A generic developer would likely seek a formulation that matches the reference product’s performance without copying proprietary process details. The main development targets would be:
- Assay and content uniformity.
- Sublingual dissolution.
- Delivered dose after packet opening.
- Stability under accelerated and long-term conditions.
- Comparable pharmacokinetic performance where required.
- Container-closure integrity.
- Human-factor performance.
Excipients that improve these parameters can support formulation-service agreements, technology licensing, and supply contracts with generic manufacturers.
What FDA regulatory issues affect excipient commercialization?
GONITRO was approved under an NDA, making the reference product’s formulation, manufacturing process, packaging, and performance data relevant to generic development. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA standards. Sublingual products may require more than conventional tablet comparisons because local dissolution and transmucosal delivery influence performance.
Key regulatory issues include:
- Inactive-ingredient acceptability for the sublingual route.
- Nitroglycerin assay and content uniformity.
- Impurity and degradation-product control.
- Moisture and oxygen sensitivity.
- Extractables and leachables from sachet materials.
- Dose delivery after opening and administration.
- Manufacturing controls for energetic materials.
- Human-factors assessment of packet handling.
- Stability data supporting the proposed shelf life.
Excipient changes in the branded product would generally require evidence that the change does not alter identity, strength, quality, purity, stability, or performance. For a generic product, a materially different excipient system may increase the burden of pharmaceutical equivalence and bioequivalence development.
What patent and exclusivity issues affect GONITRO opportunities?
GONITRO’s commercial protection is likely to depend more on formulation, powder-delivery technology, manufacturing know-how, and regulatory exclusivity than on composition-of-matter protection for nitroglycerin. Nitroglycerin is an old active ingredient, so the active molecule itself does not provide meaningful new-drug patent protection.
Relevant diligence areas include:
- Orange Book-listed patents for the reference NDA.
- Patents covering sublingual powder delivery.
- Packet, dispenser, and dose-transfer systems.
- Particle-engineered nitroglycerin formulations.
- Manufacturing and blending processes.
- Method-of-use claims for angina treatment.
- Paragraph IV certifications by ANDA applicants.
- Patent litigation under Hatch-Waxman.
- Any settlement agreements affecting generic launch timing.
FDA’s Orange Book should be checked for the current patent and exclusivity records tied to NDA 208255. Patent risk cannot be assessed from the excipient list alone. A generic formulation may avoid a formulation claim while still encountering claims directed to the delivery system, packet architecture, particle structure, or manufacturing method.
How strong is the commercial opportunity compared with other nitroglycerin products?
GONITRO competes with nitroglycerin sublingual tablets, lingual sprays, ointments, and transdermal systems. Its main commercial advantages are portability, single-dose packaging, and powder administration. Its limitations include patient familiarity with tablets and the need to open a packet accurately during an angina episode.
| Product type |
Main excipient opportunity |
Commercial limitation |
| GONITRO powder |
Flow, moisture control, rapid wetting |
Packet handling and low-dose uniformity |
| Sublingual tablet |
Direct compression, taste masking |
Disintegration and tablet friability |
| Lingual spray |
Propellant or pump formulation |
Device complexity |
| Ointment |
Semisolid vehicle and permeation control |
Slower, less convenient dosing |
| Transdermal patch |
Adhesive and release membrane |
Not intended for acute rescue |
GONITRO’s best commercial opportunity is a high-performance excipient and packaging platform for rapid, unit-dose transmucosal powders. The opportunity is narrower than the broader tablet-excipient market but offers higher technical value per unit because formulation failure can directly affect dose delivery.
Key Takeaways
- GONITRO uses nitroglycerin in a 0.4 mg sublingual powder format.
- Mannitol, povidone, and sodium starch glycolate support bulk, cohesion, and rapid dispersion.
- Moisture control, segregation prevention, and packet dose recovery are the central formulation priorities.
- Premium mannitol grades and co-processed excipient systems offer the clearest supplier opportunities.
- Packaging performance is as important as excipient selection for product quality.
- Generic developers face technical risks around low-dose uniformity, sublingual dissolution, stability, and delivery equivalence.
- Patent diligence should cover powder-delivery systems, packaging, manufacturing processes, and Orange Book listings, not only active-ingredient claims.
- The most defensible commercial opportunity is an integrated excipient, particle-engineering, and sachet solution for low-dose transmucosal powders.
FAQs
What is the main excipient in GONITRO?
Mannitol is the principal bulk excipient. It provides powder mass, supports flow and mouthfeel, and helps achieve accurate unit-dose filling.
Does GONITRO contain lactose?
The FDA labeling identifies mannitol, povidone, and sodium starch glycolate as inactive ingredients. Lactose is not identified as a labeled excipient.
Can a generic company use different excipients from GONITRO?
Yes. A generic applicant may use a different inactive-ingredient system if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and performance.
What is the largest manufacturing risk for GONITRO-type products?
The largest risk is inconsistent distribution of a very small nitroglycerin dose throughout the powder blend and into individual packets.
Are excipient patents likely to block a GONITRO generic?
Standalone excipient claims are less likely to be decisive than patents covering powder structure, sublingual delivery, packet design, particle engineering, or manufacturing processes.
References
-
U.S. Food and Drug Administration. (2016). GONITRO (nitroglycerin) powder, prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.
-
United States Pharmacopeia. (2024). USP-NF: Mannitol, povidone, and sodium starch glycolate monographs. United States Pharmacopeial Convention.
-
International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
-
International Council for Harmonisation. (2005). Q8(R2): Pharmaceutical development. ICH.
